Control of the lentiviral vector vaccination field
due to a broad & solid intellectual property position
In 2007, THERAVECTYS & The Pasteur Institute have executed a worldwide exclusive IP licensing agreement
covering the use and the production of lentiviral vectors for vaccination applications
Prophylactic & therapeutic human & veterinary vaccination applications
against all pathologies & pathogens, incl. cancer.
Production & commercialization
of GMP clinical material.